The Resurgence of the Biotech Market
Recently, there has been a buzz in the biotech industry with the S&P biotech index reaching levels not seen since 2022. The question on everyone’s mind is: Is biotech back? With pharmaceutical deals with President Donald Trump alleviating pricing pressure, a surge in M&A activity, decreasing interest rates, and a resurgence of IPOs, it seems like the biotech market is experiencing a revival.
Expert Insights
On a recent episode of Post-Hoc Live, Stifel Investment Banking’s Tim Opler, known for his insightful market analysis, shared his perspective on the current state of the biotech market. Joining him was John Carroll, the founding editor of the publication, who delved into a detailed examination of dealmaking trends over the past year.
Stay Updated
If you want to stay informed about the latest developments in the biotech market, tune in to our YouTube channel for live discussions or listen to the podcast on Spotify or Apple Podcasts. Don’t miss out on valuable insights from industry experts.
Thank you for watching!
— Drew Armstrong, Executive Editor
